Company Registration Number- 8013670 The Chanty Registration Number is ". 1147506 Ocular Melanoma UK Report and Accounts 31 March 2025
Ocular Melanoma UK Report and accounts for thè year ended 31 March 2025 Cont•nts Pag• Charlty Inlonnatlon TrvsloM' Annual R•port Statèment ol director•. r•$pon81blll1 Indp•ndent Aceount4nt's R•port 12 14 Funds Statements... Staternent of Financial Actmti Statement of Financial Ac1M'tS- Piior Year stalom•nt Movtrmènls in funds Income and Expenditur• account 16 17 18 19 B4l¥n¢e •h••t Not•• to thg a¢¢ounl• 21
Ocular Melanoma UK Company Regisiiaiion Number- 8013670 Trustees. Annual Report for the year ended 31 Mah 2025 The Trusiees ptestnl Iheii Report nO Acwunts lor the erwJ¢d 31 2025. Vthch also comprixs the Directorn, Report required b¥ the Compan$ Acl 20f&S. R•l•renc• and administrallw d•tall$ Th• ¢h•rftyn•rn•. The 9# name ol the thanty is". Oculw M¢lan(ffia VK. Th• ¢h•Fity 18 4160 kno•) byits opÉi8iwwJ nump. K4el•nwv IJK. w•¥ioustyOol VK {¢W•d Augusi 20241. Th• th•nty Fooislered in EwLqThJ & Walès wth the Cth1ty & W•$ ICCEWI with chairfy numbeT 11475C6. The th•rity doos not owr•t• th any 08$1Uom. L•g•l #thi¢lur• olth• ch•r Tho thaiTrty Is conshted as • cory•rrylMnited by 9u•r¥nl••. regl•[8d comple8 Acis. Tho 9OWrning documerf of Ihe ¢h8irty i• th• •nd ArfKlei of A••og•bon •st•thThJ lh• comp•ny under company 91lIOn. Th• 9o%%rning dowvnl Is dai•d 26 M•ith 2012 Upd8hd Artidès ofAbsooabon •nd SpecJ•l Resolulion 4re d•l•O 20th Au9U512024 Thwe ire M r•sirlLM8 in do¢wMnli on th• op•r•kn ol th• Ch•rty N on li Sn46knèni powers olhw Ih•n Ihoi• imposed by Ch•Dty L•w. By op•r8boD ol •1 Irusiees rÈ dir•dors und ITh• Comp•nw Ad 20¢¢ •1 t1ir•dor5 w• Iru•l8•1 und•r Char.¢8 ha responsi1th•5. J$ suf. uTrJ•r both ¢PInY aThJ ¢h•rity9tiOn. trUSte•s •r• 1 indi. Th• prI1p•1 op•r•Vng •<ldTw. I•h numb•r, •ml •ndw•b •ddMA••# ol th• charlty•v•.'. 139 LaThj Road Slough, Berftsh UK, SL3 7DZ Telephofiè 01753 357771 EmaN Ad¢J$ Info¢omuk.org Web Addrnisw¥M.omuk.org The regislered offiee ol Ihe ch•rity for Aol purposes VA tr A5 fv op•r•ts"rwJ •ddrv5$ shown abo. Th• Tru¥ts•• In offi¢• oh lh dat• th• Trportwu w•r•:. Mr Ntil Pearce Wison Boniamfft Mrs JoanM F- Ch•k Mr CO1 White Mr5 Chartotte Eth¥•rds- Tr•asur•r
Ocular Melanoma UK Company Registrabon Number- 8013670 Trustees. Annual Report for the year ended 31 March 2025 Th•lollDwlng p•rnon¥ ¥•r4d ** Tvu¥t• duvlng th• y••r•nd•d 31 flarth 2026:. The Irusl¢es who seryed as a frle M Ilw reptyty pentyj. 8ThJ. rf aFWic8t4È. Iheii (fats of wpwtmenl or r•sHJnabon durtny th& )Yaff re..- Appokn Mr Neil Pearce Mr8 Mison Benjarn Mr5 Jo•nn8 Frtr- Chair Mr Cohn WNI rn Charlolte EIMt4rds- Treu An Iru$18 S 8110 m•mberA oflN7 thonty. Obl•cts and acti¥StS•$ of th• ¢harlty The purposes of the ¢hrhy. ocOr Mel•norna UK Is lThe ordy VK ch•nty sol•ty +J•dtid to I14)W p•0• all8d8d by tsr md•nom8. EstabHshqd m 2009. haw b••fi W0dI1vI (w•¢0n •ThJ cMw•i8pJn•lo iupport 2011. ¥0 that Inne rw• diagno¥ts h•$ 8orn¢•hw8 10 WlthSl•ndwwJ. vxxK419y1nt. Ind comrnunity th81 c•ft m•k • I1 It0lin0. LkJrtrvJ the 2024r25 fiMrw•l >Y•r. we tyjr nam• from 0411 IJK to Or#A•r Mthom• IJK. Th• name ¢h•nge W15 lorm•ty rtg1$ièred on 20 2024 •Tr1 •5 made lo dirrfy. ensunn9 Ihot Palienl¥. f4mili•s. dinityans and slalehows c•n more •as1ty lewD th• C47nditson w• SUPPOfl. This ch&rMJo supporM our oNJtiiry work lo raise •w•reMJs. Jtr•ryth•n wr¥t•nth. 8ThJ conned morè p•Wg offected by orJJlr mdanom• Tilh lh• 11ghl lOr¥bon thnd support W• Ire d8lemln•d to drsNYt Impmwm8nl$ io peoplè can ¥ith mo10M•. Thls tkn b• • dev88181in• uncèr. w wo are 10 •nsure people •cc•6$ lo •lleaib trèalments •nd Ih•l d•ar Palhw4ys •r• In plau. all v4he >tn¥ryi lo provwjv specwhsi supwt 10 petsp whg need IL Wh•i i• oCur rn•lanom•7 OVr m•lnoffl• th • of •yè. - Vve kt)ow approxim•l•ty 750 th• UK •r Ily h•w ••th •rKI Iho8• peoplo are Iety lo nee¢J support. . W• know wo patts in thè VK wth m•lww• trt fflgy •diusb"ng 10 life •fler the¥ di•9no¥lB. . We al30 knowlhai one In ewry pe¢•le heaflMyrt•d tr•otrn•nt rfthè l)lpred¥ OuJlar melanDma indude$ ¢•ncrs. u%•l and conjunctival nl•rK)m•. u81 Man0m1 In(¢5 tho ir45, ttsrd or o118ry body. Both types of m•l•noffta can me&$1&& {w8ad) to 0r organs. wilh the Iwof typIlty in¥d%d in 90% of uw81 melanoma ca. 11 otular melarM)mo sweads to another or9an. rt 15 curenty irab. Som2 tre&trnents ethnd lrfe expfrctoncy and improve qu•lty ol Sle for le p•ti8th. plnIs un f•r +JiifvAbes OCC9 Ise IrealTri8nts and tlini&i trials. Ocular raTroma rJ usualy (k5co¥red dwifvj a examina1 or when Ihe P81ient evrien3 $ynpl¢ms ènd goe5 to their GP ¢r oplomeirist. optofflebi51 or GP su¥cts c4neer. IY sho up4enVy refei Ihe Pat1 lo iheti loc•1 OphlhalrnogY departmenl. Shouhl agre8 the rnnrm. Ihey w41 refer to ol tow $poi¥ahst tres. Glw¢Jw. Lwpool. Sh8ffi8bJ N LoThkn.
O¢ular Mlanom• UK Cornpany Re9istrabon Number- lo170 Trustees. Annual Report for the year ended 31 March 2025 Why (kular IA•l•norn• LIK n••d•d7 peop ocular rnelaTroma can feel very th. The li ar the pffogn05is often s ovwwhelmfflq Ih81 patnls fr¢qtseY repon OaA•r 14olanoma UK abo lo wo4Je both swpryl •rMI • wic• for IhDse r•r nCr. W• brin9 048 i098lher 8¢ro88 thè county and prowde UK.5[rfrn•ts"OTh. mel•n¢m• 15 0 rare canw. •nLI pants 8re Ire¢4uenty oxcknled (wom s mdanoma knal$. whith aws rtbèarch Iimiiod ltr netd for in%sth)8M wderti4ThJir¥. AS treathwnil propres$. we r•m•in commrtl•d to b•rrws that ptoplÈ from rK•i¥iw kn¢ty and •ppiopn•ie tare. We •1• comThtted to •nsww thot ewry p•tyerrf h•$ wpwl •nd Ii•otrn•nt they In "moty mafinw. Th• rnakn ¢Jnd•rta•n duthi yJ•i to Iwfvr kn chwtys wrpow for11 p"¢ b•nefft. Our ilfflj •nd obl•¢¢lv•• 04[ M•lanoma UK wwde$ 4rwJ nWIl¢ll •d¥ic• •nd •LVPOrt thFough varH)uo th•nrli. P•opkn tel u6 ihey Ih•y had 8btyJt Ilw firsl di•gnoMd. 40 tty •psKeci•te ¢h• Inlomaiion and support we provlde. This m8ans • Qrn•l deal to them, so we ha% plènnèd several pro10 10 Intrea our reach so that once someone 15 diagnoséd. they lÈm abOLrt Ocular Melancffl• UK. thè S•Mt&$ prowd•. •nd th•1 * can erKsw•g• w••trn•ni P•ltrM•y¥ to t• tr ••M th• w•iow•s P•OF4• lace.
Ocular Melanoma UK company Registrat Nwthr- 8013670 Trusteos. Annual Reportforthe year ended 31 March 2025 rhe main activities undertaken during the year lo furth•r Ihe ¢haYltys pyry>ose for the publft¢ beneflL To Impvow Support Emoiional & Pracbral Sw)port Our Head of Suppon B supponiw morè PeOK4b and mana9es our wmmunity Svpport groups. These ive open lo an 4ffected by r4nw. w•ekty TheDrwJ¥ prowdo 8 i1f• place lor people to give and recew support W1h any diffoJlMS Iheyf8C. PsythologI Support Conlinued lo provkle members wnh & fvnded profe$wol Support Vilh * sptrc4ali%l Hèah Psychologlsi 10 easé tr05 dia9nos tan hi%. This patients Mes throughout th• UK to Jhx fiyJe¢l w$310. Health Infoimati W• m•inlOKd PIF ncK •¢u•dilaUon IM Jw8r, m•w knfcrfm•tion r•t4or • • Iru$l¢d 8our¢8. Ow teioui¢% •r• iévth¥•d by LtyLaaNS acojricy ond are developed wth pali•ni8. 80 the conlenl ren¢ds th•l p•oplfr g¢nuiW want •rnl Med to know. W• 10 tend the wn¢ttn Informal •¥a#4t4• lo peopl•. Wllh IhE l•unch of ow n•w w•bsrfv. (Y••l¢d • for trusied. (4••r 8nd upio4ai• formation. 11 1$ Inged by 1189• to heKI woF4• fvj %th•ithey need wblhoul ft•ling onvhokned. Communty Supwt Ai rnenlionod •bob, w• re981 Mlinè s•38ions for peoF4è 10 tom• wtrthtrr to femow rnd•bon •r faolh•t• pt•r-Itryef SUPWt orfv. W¢ lo ¢•¥elop wr kx•l •mbou•dor wogr•mmo so thal
O¢ular Mglanorna UK C¢rnpany RfrgtrabM Nwrtr- 8013670 Trustees. Annual Report for the year ended 31 March 2025 Tts Bulld Knowl9 Confefence We held 8 trI1•Y ¢MIeren, whKh rywel 4tteTrYqd by patients Ind f•fflty membern. Yel again. wè ad a record nufflbei vl wpltr ¥Jho h•dn'i èlleftd 8 wferen¢e belore. and lor So. rt wa6 Ihe first bm¢ they mel 0%rS wth the sarne cornlrtjon. which th a huge In itseN. Wa 1150 had many ld1 ertS IhÈir sh•re trr kThJ¥Afrdoo Wnh us. en6w•d fv5018lks w• r¢corded and a¥•ilable 8fier Ihe eni. so the latest kIge caubj be eastyihared. W•bsite Our n8w web8tt8 va in rts se¢¢nd pha88. c4rw4el•led bery reyivwed. I&ing to Pil-Tic 9ualty 51andard5 and added to our t•. clin trwls have 81J0 been Iddeo and wdat•d reguiqrfy wllh Ihe upp¢rt of our cl1(¥1 Adw¢xy P•MI. Ll3F Melanorna Odober In 00•r 2024. we l•unthd Otsr Me1¥ Ch#obv. * cmwJn 10 rait• awartfiois about o¢ul•i mel8nom8 •nd 6UPPOrt 10 those affeded by this i•r¢ canuf. The camp4vJn fealuTed •&•110n•t content. communty •15. cMiled in IhE fvsi Otyjr Mel•noma 08y on 10 October. marking the charity's 151h •nniKr%•ry. h res•{ m • lourti4d Increase In our soci1 media rtrach and con&d ihdiwduals n•tyorwh¥e Ihrwh in-person ff11$. This ts$5 Ihe loundglion lor •n •xpinded 8W4r•neM Inili•lN• Or. ¥Jilh blrtady sècuied. OtyJ•i Melanoma Octo1 now become an •nNal lo 4rnplity ow rnp•cl •n¢ ¢n¥ur• no oTre lac•s ffldonoma alone. Jll•tir We Pfo&u¢• • rt9ul•i bLlkiin lor membern oibYr#J on ow work. lo b•N¢¥ wi prowde. and, importanlly. infoFm•iitin on how ppIe c•n share th811 •Wr¢t th us or ded6ion4n8k8r$ to ImwowThnts. AdvoG•cy We cont1rwd lo •d¥oc•t• kn p•¥8r41 •Thl l•mkns by ffl•kwy th•ii 1¢¥ thp• Mllonal con%rnaiions on er•. res••rch and ts4)port. W• contributed p•bènl pvrspvctss lo re8••rd% ¥tUd. en9iged with •nd polwakers to hJMghl th• i••hl8 of ooAar m•lanom•. •nd •nsured l¥milNs w•r• i•w•seffjeO tlesyn Through our 1P1•. p5yth0gicll 1Upp soMt Ind fonffii. g•thered rea1 Ih•l ch4lewe 94p$ In ure and profflot¢ lryroyt¢nents •croM p#itYway. Our •dvoe8cy Ihls yt¥i h•s unttftd M enSrI4 woplo ¥c<w¥ to •ft•c¥¥• tr••lm•nts. •1 r¢imbur3ernenl procv5ses •r• h•rmiry p•lN7n15. Te Is on nted it) tems oi tre8trneni ènd wilh ehemos•l beirmj Pfo¥en t• sale and efiecbw. we •re un¥•vJniw tor lo bty ¢d by NICE and NHS England. and Subsequenty funded on the NHS. We h•% rep••lth r•wd V& are rrfv Invohrir MPs10 5UPPQrt ow erforfs. •pplic•iion 10 the SMC has fioi been wbniM8d. lJt Pty5•d to mwror ow c4mpaniry in Scottand ¥YN7n rt'¥ •ppropTh•t•. Rare Commurtty Ocular klelonom4 UK r4 4 rnembei ol can02 Genefic ANianc and allend$ NHS Engl•nd C8n¢er Charity meeting8 $0 key ft$88ge$ c•n b• mmunICa1¢d lo our c¢Jmrnunrty. Ixjl also aNowJ us 10 Communicèie Ihe neeos of peopk affe¢ted by 0¢r w18nomo lo d•usKJn4nbkers (kjr CEO a150 ¥VOtks with Melanoffla PaInI Networt for Euiope and usemydats. and 6its M vanous projects 10 Improwe fv Il%s olpeople wth thy4 c4w. We have joined Cancer $2's on Attes8 to PAethunu. Rearr aTrJ Dala. as all of I0 •re8s should have a nobrobb impacl on ow ojfflmwty.
Ocular M•lanoma UK Company RegLStra1j Number- 1013670 Trustee8' Annual Report for the year ended 31 Mah 2025 To Orb¥• R•••r¢h CliThcal Adwsory Pawl We ha conbnued IOWOtk wrfh tyjw tkrneal ad p8rt110 9ain tswthoughts on htyw to rnsoN 8rfr¥$ that 4fe important lo paints Ind lo •n5we fv ¥rformalirn promde Is dnICa acvjrate. Rese•ith p1¢aln$ We 8upponed s•v•r81 rnse•ich ¥ppfrukn$ th•t we leR benefft PEoplp Ind mel wrfh inleTested in ¥Ming aboth the Impad ol t4t)cer. Al IinKg$. rf w85 aPPfOPriate for u$ lo ld Iho$o coThvorsats¢n5. bul compan5 int¢r¢sled In lo palrt diredy. wè re¥v6d th& (wastr thai would be asked and offered support the peoF4e In¥dwd. 08t8 We ha% Worked lo imyo¥• d•1• roulw)ely •¥all•tl• to res••rthers and bodi8$ 5¥ch as NICE & SMC. and will tonbnue to for better dats c•kcbon and thrYJ of data 50 ihai the noads of P81ionts are clearty uTrJwstood. Our CEO 5pok• 4t C•ncer R•se•r¢h UK'¥ D•t• cwfvr•nc¢ on th¢ ryact Al co ha% on e4fe ind how lh• eds of lar• uneer p8bems ShOj Conered. •$ risk Ilw sur¥iYal g•p befv¥een cornmon d r•r• urt•rn. Acc68 10 mèd43 W• ntinU¢d to b1 ilh ph•mou t4mpr thai an b1W• unc4r lo uea88 Ihe ryjmber ol •¥bkn to p•cyl• •r¥J lo irKy••w th• ol•ll•aw tr••im•nth boiNJ mbde •vailatl• 10 Peoplè. We conlkntsè to •ncow•y NHS Ery1j lo •kni to b• hJr¥l•LI •rKI h•¥v p•nts whM• thèy 8ppèI lo prlvi m•thcal cOmn to h•v• d•dthni ovJrtwn•d. Palkni Need Wè ha¥È expandod w mch io tr1 more owluih)ni eId th•1 the of rw• cwcer p•lk•nts 8r• not b•lng m•1 wrr•nl locw on ImprowrJ mwtalty UK. W• do thss ihrough workirvj or98nlsallM$ th•1 Sharn common qoafs aTrJ enab us lo ho4 8 •1 • n•bon•l knwl. Al Ihls wa8 •chleved wth the wpporl ol ow don$ who fundraixd for us. We rtr int¥edibfy grt•fvl 10 Y•r th•r •fforts Tr•r. •n*4•d w lo crrfrtknu• Ixw •nd svpporf peopl• lThrough soffle Very diffic1 times. Thè trnitè•i h& h•d to IPbt Chartrf CLN1¥r'1 ¥Mldance M p¢ beThryfrt In m•n•gry th•
O¢ular Melanoma UK Company Regtyaiion jmbr- 8013670 Trustge$' Annual Report for the year ended 31 March 2025 Structur•, gov•rnanco and managem•nl ol the charity Th• me¢ho(ts used to rKruit and appoint ch•rity trustee5. GOrnIng Docum•nt The or9anisabon Is ¥ th•ri1th comwy knirted by gu•rwtse. wwaled on 30 M•rcth 2012 regk4tered •$ A chanty on 30 May 2012. Tl company was Stsbli5hed undet • Mamorwdum olAS5111)n which &SbliShed the object$ and p¢Mrs of fv thantabkn cwpany and is 9o%wned Lder Arbdes ol Assoaalion M•n•p•m•nl Commltt•• All Trustseè 9•5 and their M)e v¢Jntsrty and re(•wd no b¢ThJfts frrlm th¢ ch•rty. Any expenses red•imed from th•nty •re Gel Oth rfi rxiie 8 10 th• a¢6. Trtssle seTht for thie• ars aThJ m8y be ro4l•cl•d •1 Ilk? AMu81 Gen¢ral Meeliry The eoard tsf re¢lOrI. topitr wth the CEO. TN•ts• Ind¥¢0n Twsiees ha% b•en •pwnied Ihe 10 lead th Chaty OTh h11[ of th• rr•nthr¥h. •j •r• mix of peopte who eilhei ha¥t xisliThJ kn119 ol Ocul•i 14elènom•, •thw ai medKal profe0 or patsenl or l•rnily of p81ifrnl. or wh¢ bfifvJ rctss•ry wofe5shinal expertw. TNst•es afe •lso dlr•thoi8 iegisiered wAh CompanKs Hou5•. A Gornpreh•Trsive Iru5t¢¢ Infoimabon p•d Is sUPd 10 •ich busi•è. uo•&nfarnn¢•s 10 the guts1•n pub15h8d by lh• Chanty Cornm¥0n InJstril •nd byCompanie% HOU (for th'redorsl. Otyihhatloml Struttuv• Th8 MaDagemeni Committee 18 rewnSib for tho stral¢gK (eclv)n and po of lh• drty. Th• CEO hi# d•kng•led re0nty IIOM the Brd lor the tsV8faM opwabon ol the ch•rity. 8ank•is CAF B•nk- Kjrys Hil. Wtsi M•llnvJ. K•ffl. ME19 4JQ Nibonl WeslmiThsler 8•nk pk, El Ctym. Enfkl CSC. L•• Hou. B•irs Road. MKldbes•x. ENI IFD sh•0¢1 Uonk. Lut•• Hous?. WaryHI Park. Th• Drf%*. Gml Wafley. enoOd. E8s•x CM13 38E
Ocular Melanoma UK Company Regisw•tyon Mber- 8013670 Trustees. Annual Report for the year ended 31 March 2025 Flnan¢lal r•vlew The charity's financialposltlon at the end ol lh• y•ar endod31 Alarch 2025 The finanoal posm¢n of Iht chanty at 31 Marth 2025 •ThJ comparabws IDr wior perh. 4$ more I deiaikd the ac¢ou)18. c•n be summan 8$ lolw- 202fj 20 N•t 7.442 16681 Unre811i(thd Ren• Funts LIble lor g•n•r•l purpoili olth• (hrty 58.$49 41.408 Resthctsd ft•bn Fund 26.908 36.607 Totsi R•8irki•dFund• 36.607 Totsl Fund• 85.457 78,C115 Flnanclal r•vl•w ol th• positlon al tho reportlng d•t•. 31 Al•rch 2025 Th• tru¥l805 conikjer Ihe lIn• tyy the lo hoN b•en satiif•(lory.
O¢ular Melanoma UK cornpany RegIStratn Number- 8013670 Trustees. Anrbual Report lor the year ended 31 March 2025 Pollcl•s on re$eryes This rtsenffts policy aim5 to tslabhsh gtlklekS lor apprwi•te ol reserws thai Mel•nom8 UK should m8iNaln. The reseTh$ polcy he enswe Ihai 0¢•r Melanoma VK has fin¥naal iesources 10 fuW4 ils rni$%n and obiecbves. respond to emergenues. and manage r5. The reser5 polcy also piowde Iranspareny and acctyJntswy 10 0¢r M•lwm UK'S si•keh(4Yw8. w)c¥Jirv4 dmori. ¥olunle•f$. 8iafl, and btnefiL?•tia8. 4alure ol rour¥e6'. FN the wrposes ollhis polw. reserNs are defined as thai ale hDld 91lN7 Mnm•di•t• ne•ds of OLiJlir Melanoma VK. R•serws bolh unrestricled ond re$bicted luTrJ$. l. Tir9el Re3oryes' OfJJlor Mdanom8 UK shoulj m•inloTr a 18rgel iew% lovel é4uwaknt to 1 le&si SIX rnonlhs of oper•iirffj ewn6es. The 91 ietèMs wim be r•ed nnuty and adiusttd •$ •¢¢d b•6d on O¢ulaT Melinoffl4 VK'S finangal •)n. nsks. ond oppryhmrts. ?. Minimum ResoM8'. OoJ18r Mèlanoma UK 8h¢yJbJ main1Th a le ol tht lo three month8 of owraling mirMmw b¢ revwed annu•hy •nd •dwsl•d • rrtedod bas•d on Owl•r M¢lanoma UK'S F¥T$¢j•1 sduatson. n5ks. 4nd oPPOnL•S. J. ol ReMws. R•swb$ ShOd b• u••d foi spetsfic pu$. suth 1 •m?rynEieS. unexpeded •xpen8•8. 0110 support now IrMliatsNv R•wr4fes shwhl nol be uled lo opw•tron•l dtfiols or iè fund wopr•m5 th•1 Bre rbDI 51Lilain•bl8. 4. Inw3thenl ol R•8eMI" Rts•r¥eJ Ohould b• MMisi•d kn • m•nriei th1 bIr¥ $•hty. IV4Uty. 8nd •1. ThÈ Inve•imenl slratsgy ro¥w0 •nd •ONJ • n••d•d b•s•d OTh 01 linr¥ UK'5 fin•ncJ81 Irtty¢n. nsks, and OPPOnWbthes. 5. Fleportlr¥J on Re&8. OoJ•r K4•lanom• UK i• report annu•y on th• of its r•swws In il flnancl81 $18itrrnenl.Ths policy •nBw•s Ih•l Otyl•r Melanom8 VK h•s fi•1 resour0 10 fiAN ili miuk>n •ThJ obl•¢lwi. r•wnd 10 •moryJO1m. rn•n89• Tho polity proMd•• guid¢kn•s lor I •ppropn•t• of reseNe5. the u¥• •TrJ Inwstrn•nl of le1. and i¢porfing on reserwi. Th• p¢ty¢y w1 be Ited aru•1Y aTrJ adiusied a8 needed bastd Oculif Mel•noma UK'S fin8nt411 iihmbtin. nsk&. •nd Avall•blllty •nd•d•quKy olass•ts ole•¢h olth• funds Th board ol tru$l•es lised th•1 th• L•rtVs 86aet6 th ••th fvnd ar• atA48bl8 •ThJ adèqua tti oblalions In respèct of •ich
Ocular M¥lan¢ma UK Company RegtratiOn Number- 6013870 Trustees, Annual Report for the year ended 31 March 2025 Plans For the Futur• Summiry ol pl•n• lof th• l¥tur• •nd ¢h• tru¥t•H' pwsp•¢tfv• olth•fuiw• dlr•¢llon ol th• ch•rhy. We striw to pro thfr ur•. •nd peoF48 receiw. In Ihe ahead, we will our w¢th so thal onc smieone 15 diagmsed. tty 8M abtyth OcLd4r Me18nom• UK and tho promdp. and th1 bt•imeN p•lFrw•ys e¥th to eas• tho pressures wa know face. We HleniiFd seTrJeral ways lo red I wS8ur. str•nfftnlw ow ¢•nty $0 it [• help ppIe dnd heir Iaffld Ihiouyh thèse diffKth Iffi)eS. In •ddition the s•Tri¢ts this W. wim its1orS ow •ffort6 to.. 1. Rtduta del•p In aece$w IOInI lor met•51•tKthx•w •nd 2. Inu••v our Ihai reduc ise4a0 •ThJ ¢tslres¢. W• 11 do Ihil by". Improw Support . AHo¥Y P8bènts its book sthtduled c•b 80 they c•n ppo • th•1 f••lo man•g••bl• for Ihorn. . 8uild • peer.l¢Fpeer nthork 10 5WPWt •TrJ 9uMJ• they p•ii•nts 0ghOul diagno&ii nd ty•¥lmenl. - Conlinue lo develop our ¥uhe of p1nI bookleis aftd 184or IS iTrform•kn lor ow websit• so woplè c4n •IY find Iiusiod. (tvant Inform•tson th¢r¥ef they ntred It. - Invease •warènt81 of d)it&l th8ls by sharirJ all nn slud5 on our wébsil•. r•co9niiing Ihal Ih•r8 1$ no olhel 61TrJkn r¢8t)ur¢e brryiro opbons 10gtlhér IDt our tommunty. . Introduce • th•thoi on wr TM•b•l• lo W p•¢l• find •TrJ wppNt. PlJ11Y of hour•. 8ulld Knvl•do• . Launch a sumyto deI•D 4J•y4&Wy iw¢tolorAlar MellMI on p•opl• •nd Ilirf•mkn•. * m•k• the InsvJh15 widèly av•ilaN• to support unpr0NwnIl m ure ond st1¢ desvJn. - L••m from th• eupATI p•¢1 Expert TriniN4 Proyramme 10 $lrewth•n wr ablO cntribute mtanirylully 10 re6o•r¢h dilpJui •rwJ •nsw• paint perw¢ty¥w r•m•in c•ntr•l to (ln1 d¢dJion mikity. . Atlend key m•eVng¥ in ¢h• IJK •nd •bFo•d. irhJdty spe8king •1 t1 MY Dlta t1•rence. io th• Id expeiience ol o¢ul8t mel•nom• r¢present¢d wheievèr dtash)Iw ale rn•d•. . RepreseTht our eommuThty atsoss n•Donal 8nd InM•)n11 lorums. NICE, SMC •TrJ NPIS fe¥i•WL¥. 8nd Ihi¢)ugh wr CEO'S ro vmlh EURACAN is ePag lof 10
Ocular Melanoma UK Company Regisii81ion Numbef - 8012670 Trustee$. Annual Report for the year ended 31 March 2025 Dr Resoar¢h . Begin a Kheme lo wport •arty doted ol oc4Ar mt1•r. rttww that in the •bsenc ol a oJre. eartydiagnows Is ore of ihe stron9e$i opportmthes to Sur1 I1 qaty01 lrfe. - Conlinue lo Tal awarers$ ol Ihtr disease so ptoplè ate diagnosed sooner and h8¥ betler a¢8$ 10 limety Irealmenl. - Share rtal-worfd pa1 knshjht fr¢th s8Thico5. raIrS 8TrJ lnK4• wr51•nd Ihe thaleng?s Peop fate and ilL¥l$ thattruty rÈlIÈGlpt1ffiOeds. Be sus181•ble . Expand lh• te•m lo wport OLY ndIlIer our HO of M4rqtsig and to F4n wo to supwt more peop. indudifvJ Ihrouoh 1911%$ 8uch 8$ OcL4•r PAel•nomo Oclober. . Entouiagt fflmbors 10 shir• h(w our support has hewd thtm. strnn9trrw our commuffj and Ing oth¢rs lo lundr415¢ or gel Invol¥¢d L8unth an overse•$ th•lnge 8ni in rtspmse to member r•qu•st3. h8ty"r¥J diwrsify Inme and ItfellglThen ummunilyen9ageffltrni. - Vs¢ all •vailabK• r•$¢urees wsely $0 wr smal te•m 1$ poth.( r rt r•n have thè W•atsil Impacl. - SIFtnoihen Intem•l prOlIeS 8t)d dillrt•l lrtls. th8 IrrtiothKtion ol ow ch•lbol. to ensur• we Femain eiren1. responsive aTrJ resthenl as w• grow. E¥eMhing 0¢4T M•l8nom8 UK h•s •¢hie%d toniirn• to eom• fvom •he•r dedlcakn i p•s8lon to make real th4nge In the livès ol thre 4ffed¢d by IhL4 dreadfrjl cancer. Wo will unbr¥Jo uniiwe h•¥0 a worfd people wth oC•r MOrn• th%. and Iw w•1. O•tsll¥ of Th• Ind*nd+nt Examln•r Tr8Y Prflchard BA FCA Ch•rt•r•d AcnIan1 255 Povnon Road Wal¥sey Morsoy5kl• CH44 48T 11
Ocular Melanoma UK CLPanY Registyaiw P+umber- 8012670 Trustees. Anntsal Report for the year ended 31 March 2025 Stat•m•nt of the Dir•ctorJ Trustsets. R•sponsibiliti•s Th¢ charitys IfU5tee% r¢ reSpOabl1 lorthe y•parabon of •¢t•rdan( th¢ lerns 01 th• Companies Aci 2006. the chan1S Ad 2011 and Ihe Ch•ni$ IAccounl$ and Reports) R¢9ulaiions 2008. Not<+thitst)diNJ the reqwement in Ihe exlanl slalulory ChanbE% (Accounts and Report$1 Regulabons 2008. to prepare IhE f•81 siaiements m adance with thtr SORP 2W5. In vhew ol Ihts fact thai Ihe SORP 2005 h8$ been wrftidr. Ihe Trusietrs dewmined lo Inlerprel Ihr4 responsbility 88 r•quring them lo folLw rJmTIt besi Pl8Clice 8nd prepare •c£oun15 •ceordtn9 lo the FRS 107 SORP Islatemeni of Recornrftnded PracbEe fN A(Untirj ¥rwJ Reporbty bychanbesl 2015. (as am•nded by th• Bulelin issued in o&ob•i 2018 and •pWK•ble lo 4 •ccounbng penods orb ry after 1s1 Jnuary 20191, lThe SORPI, In partKutsr. Ihe Compan8 Atl 20C6 •nd th•nty 18w r•wir• the Boafd of Tws15 w prepare finanual $wtemenis for each fvwnu•l ¥r give a ar of the $18to ol •ftair5 01 as ai th Ind ol fkn•n¢ial •nO of ihe surplus or olV chrty. In pwpwitw Ihose fin•nc4al statements lh• B041d 1¢ r•quired lo ' pr¢pirt ctsunis in 8¢¢Otd•nce with Unlled KK4dorn Genera Accepted Accounliw Pi•cbce litrt¢d Kirydcrfn Acco)9 siand•rd$ •TrJ law}. . 1cl suilitdè act0 pokw8 ond applytsm conwttrtty. - m•ke hJdg•mènl• •rd e$lim•l•$ Ih•t •re rfr•sonablE Ind wnI.. . prepaie Ihe finorKi•l ¥l•l•m•nts on ts going eont4m basrf •$5 il ts kn•pproprfil to pr•iume Ih•l Ihe thinty Contira in busms$'. &it• whèih•r applic•ble •¢ctyJnlirvJ ilandarfs st•l•m•nts ol recommended praeltce how b••n fol0. Je& t• any •J•partw•s •rwJ •xptslrd lh• T l•w rtquir•s Ih81 th• tyustse$ mu51 nol •pprow I urths they we ihal Imy gi¥ Irue Ind l•ir ollh• st•k of all•irn ol Ihe ¢h¥iityand of th• xxphjs or d•fKrt of thè tharrfy lor tho y•r. Th¢ Trusl•e% ar• also rsponb lor ma181n9 •deqvat¢ 4ccouniing ¢05 thkh dlsdose wilh r•asorSab •CCUfa¢y Ot •ny trml kne finanail posbM of the (hanty ond suffic io show and •xpLgin ch8ri1¥8 tr•n$•thons and •n•ble lo enswé Ihii the fina]•1 $tslerr¢nts compty wsth Ih COMp4n$ Acl 21)08 and Comply ¥Mlh reyallOnS m•d• unaer the ChaIrtl Aci. TFy 81e •l$o re5pon51ty1e for $4fegu•rdiw the •$5•1s oi the rnt lor rn•irmb sbps for the prt¥•On fvJ dCli0n of •nd olhw thLl81ths. The TnMleeB or• •150 r•sponle fN Ihe conlentl ol the TnAte•$' ff•port. •rbJ Ihe #lalulory re8pon6iblhy of Ihè Independènt Examk)•r fft relalton lo Tw$le•s' itporf its Imited 10 examlnwy lh• report and tnsunrvJ th•1, on Ihe 14¢¢ 01 the report. ther *r• no matèrial ¥nth the fffjures di8dos8d In I finonry•l 12
Ocular M•l•n•ma UK Cthmpany FQe9BIJn NLf-Bot3610 Trustees. Annval R¢port lor th¢ year ¢nd•d 31 M•r¢h 2025 M•thod of pr•p•rntlafi ol ao•ounts - Sm•ll •omp•ny pr•vlslons Th• financ$ 1ts1oments arn on p•gH 16 to 35. The fnancs•l slalemtrnh h& bèèn woporEd wnprthrvJ FRS 102 SORP Istsm•nt of R•comrnend•d Prarlw Athwnlbg and R•porfry by ch4ntl 2015. (• n•nd•d by lh• BuM•tln issued in October 2018 and appllt4b lo •1 tnbr¥I pErS WinnirJ on c¢ aftei 1S1 January 20191. (Th• SCIIPI, and kn •ccthirK• Repffii 102. l•fknthe 111 Jwu•ry 20161 Compan ALI •ppkbltr lov)nwNlS Sutyd to th• m•l r•0 MRS C EOWNIDS Dii•Gr •nd Trnth• 13
Ocular Melanoma UK Report of the Independent Examiner ¢0 the Tnte olthe ¢harrlabl ¢ompany on th• c¢ounts lor the year ended 31 March 2025 I repDrf lo the TfUStee5 on ry exarninalion of I1 finanr} slalemeThis of Iht thartablt tompany on pages 16 10 35 for Ihe year ended 31 March 2025 thich have been prepared Iri aCtL¥dar wlh IhÈ Charthes Aci 2011 (the Acii and ¥%ilh Ihe Finanpal Reportsry Slandar(1 102. (ellects 151 Jarxjary 20161 as fflLKlified by FRS 102 SORP Islalemenl of Recornrnendett Pracbce lor Accowlmg •nd Rewtin9 by Charthsl 2015. las ameThJed by Ihe PuHetsn issued In October 2018 and appk¥bk to a# accwnbrwJ peviods btguKuTrJ an or after 1$1 J8nuary 20191. (The SORPI, published by the Chanty Commission in Engtjrwl & Wa5 ICCEWI . •nd undÈi the hisloncal cosi ¢Mveniion afid accounliry pOlK Sel page 21. R•sp•Gtlv• T•sponslbllitl• ol th• TnMt•ts •nd th• Ind•p•nd•n¢ Examinv•nd th• olth• rnptsrt As dèstribed on page 12, yw. Ihe tharrtabk corwanls TrusieeÈ. Trhtho are al&0 De£l8 ol the Comp8ny lor the purposès ol Compary law, are re¥rble for ts prepzTtth of Ihe financial st•iemeffl8 in accordance %h th6 Companie5 Act 20(N8, the Chanls Ad 2011 and all olher applicab arwj ¥Mth Unrted Kingdom Generally AttepiÉ4 Actouniiry Pract. •ppk•blp lo )ller eribW. lor ublfied Ihe thC4a1 sialemenli ivt a Iwe And flir vw. The Tntsle•8 eonsider Ihal Ihe audrt reqLriremtni ol Seclth 144111 of the Ch8nthe8 2011 Ilhe Acl) does nol apply, and Ihal there is no requi10N in Ihe ffmNandtsm •TrJ artK$ ol Ihe tharty for the crrtucliThJ of an JLKJit. 8rKI thal the accotsni8 ¢Jo require an a11[ In ac¢yNdance Part 16 01 Ihe cCffjpanS Acl 2006 and Ihal no member or membeis have requesied an a111 pwsuarn 10 Section 476 of the Companie5 kl 2006. As con8tqu8nce. Ihe Tru81ees have elecled Ihal the finarthl ¥latennts be S)10¢t lo indepondenl IX1rn. HaVg sali¥fied my5dl Ihal Ibe slalements •r• I¢ requirtd lo be LMNler •Ny g•l yovision. or olherY+i¥e, •nd are el1b10 for indewndenl eufflmalw. it io my rewnsknthty lo- •) ¢x•mine rinanoal 31ilemenl$ of th¢ ch4rfy w¥Jef St 145 of Il A¢i.' bl folW1he applicable p¢o(dwes in the w¥en by b)e Charity CofffflM2•)n undw 14515llbl of the Ad. 81814 of I10P••fit Ex•mln•fs St•t•m•nt •nd 0p of wtyk und•rt•k•n I r•p¢)rf kn re•pecl of my exarniMbon ol 114ry si•inwis t•rrtl fAI 1145 th¢ A¢1. In Corrying out rny eyaminalicffj. I haw folml all the applKaNe trediw5 given by the Ch•nty Comffliision under seclion 1451Sllbl of Acl 3eitsThJ out the ¢JU1 ol an deperJenI examinEr In relation to tU1j ol an dependenl examinalion. Ind•p¢ndenl examin8lH)n Indthles a revwi of the •ccounlirvJ records ke by Ihe ¢haritab ¢¢)mpany and ol 1ccotIng Sy51em$ employed by Ihe Larf8b tompany and a tomp8ri$0n of Ihe finantial ¥i•iemtnis PTe5enled wlh Iho¥e recwds l also mdLKlts u)n8Klerai1) ol any unusu&l rtems oi dist4osure8 in the financial siaiemenis. •nd sèekty èWn•lK)ns from you. as Tntsiees. conLniNa iuth matters. Tho purpose ol ihe examinaiio¢i Is lo esiabh'sh •5 lar as possible Ihal Ire have been no breache8 of taMy giatsOn and thal, on a lest ba818 of eyldento rdevnt to Ihe m•Je. the rm81•1 si•tennl8 cornpty %•lh the SORP. The Pfocedures 0ertakefi do noi wovmle am the evhJenc Ihal te rnqwred in an audil, and 1rli Supplied by the TNstee$ In Ihe ctyjrse of the examin•th Is nol S0 lo audd tes15 or enouiries grKI doe5 riot cover ill Ihe matters that an audrtor cmsider wi afriwThJ al an opin. The d•nr4 •fvJ f•>xl1 of •n •udit goes boyond Ihe Iimrfed 888urance that an inden1 examiOn can Consequerilty, I do not ewess arb awjit op¥rAon I1 by ts finawl $tat¢menlJ, and kn partirxdar, I Èxyes& no opirmon 8$ 10 thelher Ihe finantial statements give a and la view ol ol Ihe carty. and my report is limited lo the matters s*1 Oth In lh2 stjternenl be. l F4anned and performed my examiThabon 80 as lo sabsfy myself that the ¢)bae5 of fv irKIBpethnl ex8rnin$ ore atheved aTrd before report l oblaimd willen 8sxv•ncesfrom fv Trustees of•1 mattern. 14
Ocular Molanoma UK Indop•nd•nt Examln•rf StIt•rn•llL R•port and Op4nlon SL)ieLt 10 h"mrt¥D IhÈ sccye of my as del8led above. I ha¥e compleled my exarninabon". and Can confimi that".- The accwnts trf thorilaNE comp•rw ire reqred to be alite thjer Part 16 of Ihe Comparmes Acl 2LX16.. This & rnport respeca ol an eXamal)n tyjl urkjtr 145 of kl arKI vAth I)1$ gwen by Charty ComnNSSKffj under Sec1 145(5llbl of the Acl th may be awAicabl¢. 1 that no moienal mattrs hav¢ c4)me to my tteniitin CeO with Ihe eXaallOn rrh7 c4use lo believe thal In )ny maiefial fesped- a¢couniin9 retords re not epi resped olthe dnty as by Seckn 366 0111% comn Ac¢ 2006 aThJ Section 130 of The Ch81118 Aca 2011.. Ihe fnanual slaternnls do nol accord Ihose rer4Yds. the finanual 8lalewl8 do rK¢l corryy %wih applicatrAe rewyemtyms the lonn tiJnt¢nt ol accounls Sel oul In sectiw 3% 01 Companies Act otrr Ih•n •ny re4uir¢m¢M Ih•t the aL%ounli gfve • 8TrJ farf view. ttich 18 nol a rn•tter conshyered •$ part of •n mdÈpÈndeni eximinal1ts1. howe nol been pr•pwtd In accwdance Mith th0o¥ oul in Ihe FRS 102 SOAP Islalemenl of Re¢ommeTrled Prathce forAccowlry and Repprtffj by Ch#iiisI 2015. las amended by the Bullebn issued in Oclober 2018 and JpplKable lo •ll JGCthmliNJ w)ds bÈgiMlry on LV aft•r 181 J8nu8ry 20191. (The SORPI. I haw no corTrcems and hove arJoM 011r m•llers in ¢¢w*¢tion vAh lh• •x•mination to attenlion Bhould be drabw in this reporf In order to enat4e • proper undws1•lry of Ihe fin•ntiil siatem•nls lo reached. TraY Pritth•rd BA FCA- Indep•nd•nt Ex•rri Ch•ffltrnd A¢¢4miwi 255 Foull¢n Ro•d W•llaBey Merney8h16 CH44 4BT This report was 8yne¢l on 12 202S 15
Ocular Melanoma UK - Statement of Financial Activities for Ihe year endod 31 March 2025 Statement of Financial Activities (including the Income and Expenditure Account lor the year ended 31 March 2025. as rgquirod by the Companies Act 2006) Cutt•nt y•ai CuM•nty•ar Current ye41 Tot41 Fvnd pOr Ye4f Totsl Fund¥ Fun Fundb 202$ 292$ 2024 Incomo & EndoTr•rrt¥ fr¢Jm: Donations & Lega¢i•s Chariiable a¢tMfves Other tr•ding •¢11•$ I¥1mentI A1 69.884 126.1fj6 247 sJ.sJi 939 103,133 325 45,317 520 247 53.531 Total In¢om• 09.W 180,903 149.29$ Exp•n¢uiur• on: Railing fvnd• Chaiitabk octNrtieJ 81 B2 1.777 1U,684 2.972 147.011 67.101 79.583 Total ¢xpendlturo .878 79,583 173.461 149,983 N•t Incom• lor th• y•ar 19.6991 7.442 16881 TraMf•rn b•twwn lunth N•t In¢tyn• •ft•r tra1•19 17.141 1#.$991 7,442 16881 Net mov•ffl•nt In lurK 17,141 19.6991 7.442 16881 R•conclllatlon of lunds:. Toial funds brought forw•rd 41.408 36.607 n.015 78.7tyJ Toi•l funds urrl•d ltywwd 58,549 85.4S7 78.015 The 'SORP Ref indicated above Ihe cla5sificakn of incoff sel out In lh• frrnal SORP documfrnts. As requirtd by paragraph 4.60 of t SORP, the br¢u9hl f¢rwar¢ aThJ carrnd forword lufvjs at>J¥e ha¥e been 4raed lo Ihe Balance Sheel. A separate StaternMI of Totsl Rects3nkMd G•Th Losses 15 Th)t rn4LHrtI •$ this $t•tement In¢1 •ll recogni8ed 98ins and losse$. AJI actiwlie8 deri¥e frcffl conbnuiThJ OFeratior Thè not•s attach•d on pag•s 21 to 35 torni an Int•grdl part ofthese accounts. 16
Ocular Melanoma UK - Statement ol Financial Activities for the year ended 31 March 2025 Ocular Melanoma UK - Anatysls of prlor year total funds. as requlred by paragraph 4.2 of the SORP PwlorY••v PwlorY•ar Y••t SORP lknwtttrict•d R••triGl•d Totsi 2024 2024 2024 In¢om• & Endown•rts irtyTr'. Donat# & L•ga¢K•$ Charrtab 8etwrt Olhtrr If•Jin9 a¢la'wes In¥strnents A1 42.133 325 45.317 61.ocri 103.133 325 45.317 $20 Tol•1 In¢om• 88.295 61.CQJ 149.296 Exp•ndllur• on.. Raising funds chafilabk a¢livili¢• Bl 82 2.972 2,972 147,011 58.211 Total •xp•ndtur• gJ.772 66,211 149,983 Net goin• In¥e8lments Net Incom• for the y••r 15.477) 4.789 18861 Transf•rn b•lwe•n fund N•t In¢om• •ft•r trnsf•rn 15.4771 4.789 Net movement In lundB 15.4771 4.789 RKon¢lll•tlon of lund4'.. Tot•1 fund8 brought loard $4.910 23.793 70,703 Tot fundB Ufrf•d forward 49.433 28,582 78.015 17
Ocular Melanoma UK - Stalement of Financial Actlvlties for the year ended 31 March 2025 Ocular Melanoma UK- Resources applled In the year ended 31 March 2025 towards fixod assets for Chaflty use:. 2025 24 Fund$ genorated In the y8ai as d8tail8d In tt SOFA R¢8ource8 applN8d on lunthonal fixed a65•ti Olhei applications of lunds 7.442 16881 N•t rè8oure•s avail•bl• to lund ch•fftabl• •¢tfvlll•¥ 7,442 688 Th• mswr¢•8 ors fix•d ¥is¢M ehanty fepr•s•nlS Iho cosl ol •Jdion¥1885 proc•eds of any di$po$als. Th• not•s attach•d on p•g•• 21 to 35 lomi •n Int•grnl part of th• accounts. Mov•ments In revenue and capttal funds for the year ended 31 March 2025 R•v•nu• accumulatod funds UnrnAirfcl•d Fun R••trkt•d Fuhd 2026 Tolal Fund• 201$ L4•t ymr Totsl Fvnd• 2024 2025 ulat•d funds broh1 ltyw4r(I 41.406 36.607 78,015 78,703 R•¢ooni$ed 9olrr4 •nd th8•$ b•for• transfors 17.141 9.6991 7,442 16881 SB.$49 J8.467 78,016 IFromirro unrtttrithd r•venu• fu clon9 I•V•n lund• S8,$49 26,908 15,4S7 78,015 Summary of lund• Unv••lrl¢t•d R•trtci•d To1•1 Fund• Fundl Tot41 Fund DM*n•l•d luthd• 2025 202S Z024 Revenue accumu1• fvnd$ 58.549 85,457 78.015 Th• notss atlached on page• 21 to 35 fomi an Int•gral part ofthese a¢¢ounts. 18
Ocular Melanoma UK- Statemenl of Financ•al Activities for the year ended 31 March 202S Ocular Melanoma UK Income and Expenditure Account for the year ended 31 March 2025 as requlred by the Companies Act 2006 202S 2024 In¢tW> In¢ome frw Inv¢$tmgnt incor Inlere$l TO1¥ab 179,964 148,775 939 520 Grlxs Incom• In th• year t>•for• •XC•P¢lobW knms 180,903 149.295 Gro•• Incom• In the yur Includn9 •X¢Wlond tt•rn¥ 180.903 149.295 Charilabkn exp•nditur•. •x¢'r9 dey•cwbon aThJ arncrfl5art Oeprecialion and amorfrs•bon Fundra151ng CO$1$ Gowrnanc• co$li 165,318 142 ,777 1,224 145,598 243 2.972 Totsl expendIrn In tho y••r 173,461 149.983 N•t Incom• b•lor• t•x In th• finarKlal yer 7.442 16891 Tax on surplu• on ¥¢lMb N•1 Incom• •ft•r tax In th• Ilnanc141 y•ar 7.442 18881 Retsln•d surplus for th• fin•ncl•l y•r 7,442 All a¢liMties d•rive from contsnuing oper•tw)n8 In accordanc8 Wrth lh• prS)n$ oflhe ¢¢ryan*s 2fX6. thfr heathws s)head13 us•d in Ir and Eypendilur• 0¢Unt have been adapted lo refiect special natu of t chaiitys acliwbes. Th• note• 4tt•¢h•d on pagm 21 to 35 fomi an Integr•l part ol th•s• accoun1¥. 19
Otsul•r M•hnoTD• UK- B•l•n4• Shoe •s •t 31 IA•f•h 2025 SORP NotCR Z025 2024 Flx•d Au•ts atS 10 238 2.11)J 12 82 22.W 59.027 77273 7.1¥7 79.381 1.731 5.>31 78,015 Th• l•l•l I1 i•••i• •1 •h•rfty ¥•funaDd bylh•fvndB th• •h•1. M l#11... 17 DI 36.607 38,IM7 Unr•strld FdI 17 03 S8,$4• Taiil •ttwlty fv ha¥Y bv•n •or•¢d lo Ihv SOFA underw¢trM 477 01 CompnM Act 2 Th• m•mb•rn n¢1 l•qr•d thè ctympany io Obts •n •ytht 476 Ex4mmf p•a• 15. 20C¢ ippIca#t0 ubJ•¢l lofv r£thp•n*s regmht
Ocular Melanoma UK Notes to the Accounts for the year ended 31 March 2025 1 Aeeounting pollcl•8 Pollclés reladng to the pmduetlon olthe accounts. Basls of preparntlon and •¢cow9 conv•nllon Th? accounts have been prepared cffj the accruaL% ba$$. unthr the hi$iorical cost Con¥entn, aTrJ In accrxdance with Ihe Financial Reportln9 Slandaid 102. leifec¥e 1st Jaruary 20161 aTrJ 'FRS 102 SORP Istalerwii of Rerxjmmended Practice for A¢¢ountin9 and Reportsng by chalIes1 2015. las amended by the Bulklin ISSLd In October 2018 and applicabk8 to all accounbn9 pefd5 be9inniNJ on or 8fter 1st January 20191, (The SORPI. published by the Ch&rity Cwmis$i¢n In England & WaS IC¢EWI . effeth¥e January 2016. and In acrIan¢< with am applicable law In the charty's jurisdiction of reg151ratw, except Ihal Ihe ¢hanty h•s p8re the financial statements In ac¢ordan¢e witti Ihe FRS 102 SORP Islaiemenl of RecommeThJ¢d Pracb¢e foi AwJunbThJ and Reporfin9 by Ch•nlie$l X115, 14$ omeTrJod by Ihe BUltin Issued In October 2018 and applKable lo al accounbryj perS tegiMlThJ on or after 1st January 20191.1Th• SORPI, in prefertrn to the pr•vtsJ$ SORP. the SORP 2C#)S. whKh has b8en wthdrawn. nOlStanding the fact Ihot Ihe exlAnl $l&lulory regulation5. the Charit5 (Accounts Reports) R¢9ubOn$ 2008 reler explialty to Ihe SORP 2005. Thi5 ha5 been doro to acctyd wilh ¢urnent besi kwacD¢•. Rlsks futur• •uumoioM The charity Is a pubtK befil enlty. The Managtrnenl Commrtt•¢ has r•¥ed the mw to wl¥ch fv charity h•$ expo. Wher• appropria, •ysl8rn8 or piocedure5 have t4en e5181&h•d lo milJaie the risks Ihe ¢hanty face8. Oui Regional Representatw 4¢0 e¥¢h IS$ wrth Ihe O¢LAar Melanoma UK RepFe58nl•ti¥• Handbook and •re Invited lo 8ttend a troining ses810n. Flnand41 conlrd Mki •r• minimrned ty 01 prrxdure8 kn authwisalion of all tr4ns•ctKns. Accountlng for del•fr•d Incom• •nd lrtam• f•¢•lv•d In •dv•n Where Iwm• •nd C£dI"0n relalmg lo irOrr hav• T1 b••n rn•t or unurt*nty t• u to whother thv charity can m•oi any terms or condifr'ons Oth01$• wilhin its cmlrol. Inccffi• 1$ not wnrd8d but M thf•rnd al • li•bility until Il 1$ VObab Ih4t t l¢rms u ¢ondrtns 4np05ed can be met Any grant that IS 6jj• to wrfomi•r-r•L410d Wlon6 red ITr thancè of dolN•riw the 9ood$ •nd servi require¢ by Ihal condition. or Is subjecl lo unffl colJ0$ wholy outsth the ¢gntrol d the r0¢y1 charity. is accounled lor 8S 8 liability and th• bal•nc $lwt as deferred Incorne. Deferred Incc¢M ts r•¥6•Y 10 income In Ihe r•p¢rtirs por In whi¢h wrfom)On¢e1a1ed or olhw corJrtws Ihat Iimil recognfyon I rrnl. When In¢ome from 8 grant LY donalion has not bo•ft r•wn15•d due 10 the conditions applyiThJ lo th• not t•iNJ whol wilhin the Control ol th• r•¢iwnl ¢h•tsty. rt f4 do¢losed as • ¢wtireent 88501 if r•¢•ry)l of 9rwl or don8bon 1$ prob4bl? on¢¢ those ¢oThJitsons are Thl. Wh•m tirn• r•lated ¢wdrtion$ We ryos¢d or mphed ty a funder. Ih8n the irbctyn• 1$ •pptyty"oned lo the time periods concer. and. where applKable, is xwjnled for as a Iiabslity and $hvAfn on the balanee sh1 a5 defvrred income. When grants are rt¢eNed In athfan¢e ol Ihe exFeThJrture on the acti¥ity funded by them. bul rhe are no $pe¢ifi¢ lime related cDndi'on6, Ihen Ihe is rKst delad. Any condition that allows lor the re¢tyery by Ihe dorKv of any uneyr¥Jed part tsf 3 grant doo$ not pre%nt rn10Th of the Income concerned. but a labikty to any repayrnent Y4 recogn15ed wln repaymenl tecomes probab*. 21
Ocular Melanoma UK Notes to the Accounts for the year ended 31 March 2025 Donated goods. facilili•s and s•Thflces Donated assets are recogned at Ihe ¢wrent fwr tAlue. Al suth donabJn5 ar• ret¢9fi as donation irKcrne. 8nd debited lo fixed a55el5. Donated 9¢ods that are nDt fjxe(l assets ar¢ occounled lor 4t a lair v8lL. un5S mwro¢tical lo reliably Measu tho value of the donated items. In Ihe absence of any direct evvJerK• of fair Val of dmaled goc#Js, a valtse defjved from the cost of Ihe 1M to Ihe donor or. in the tas• •19oods thot ar• expeclod to be sobJ. th• asrnated fesale Val after deducng any antr¢ipated costs of Sa#. If il 1$ imwactscabk lo measure fair value ol grJds donated fty resa. or fv co$is of valuaon outsveyh the berit$, the donated good$ are renised a5 Income wln $old. wrth an equr¥aleni ¥fioiirl being reco9ni$ed as an exnse. The ¢o$i$ ol goods donaled for di$iribvbon to terfKlar Is to be the lair value of Ihose goods upon ceipt When Ihe goods are di$iributed Ireely or for a n¢min•l ¢on$Kleration. Ihen It ¢affying amount is adiu$ted at the time of sale. 10 th• value at point of distr[tkn •r¥J the 8diu51ment IS 5hMI a$ o cost of donabon$ mod¢. The carryin9 ¥m¢unl ol any 51rtk hokl lor assessed ftyr iffyirnwnl al the date. AJI donated goods •r¢ recogniwl as donation Irwme, debsted to tradin9 stock. When trathw $lock sub$equenlly $oh#. or appropriat•d to meel an expens•, then Ihe carj value of Ihe 51rtk r¢cognwd as an expense. In accordance with the SORP, gotrjs donated for th$inttran to beTh8kiaMs. ¢onsumFIn by IP chonty are ¢n¢hJd•d ifi'lega¢i¢s and donations.. Good$ dw4led for resalB ar• inCKd 1n.1rK frcffl Ir•dity gcti¥itie5' The 1 of any $lock ol good5 dortat•d ftr ¢JBlribulvJn lo beneficiar$ ¢ deemed lo b• Ihe 18ir value of Ih05e gffts al th¢ Ilm¢ ol their receipt. If 9¢ods k1 are lo be dislributed oi for a nrfiin•l Colderat1n, Ih•n IN Carrying amount 18 subs8quenUy 8diu$ted lo refiecl lh• Imr ol d¢¢fi c051 fvr h)ss 01 Serw potential and reaceMent cost Replacement c051 1$ ihe e¢oncffjic c051 incurred rf the ¢h•nty was lo r•plxt thg service potential of the donated goods at tts rw4n txpenw In the most ecofiomK mn•r. Oonaiod $•rvic6 and faalrts lincludiNJ s•cled Siaft aTra w ol pryrtyl are indvoed in tts occounts on th• basil ol the valw of the gift to ¢hanty. AJI donat•d and faclities are r•cogNised as donation Inccrn when rK•Md. Iproythd th¢ of the 9Tr7 Gan measured reliabtyl aTrJ ie¢o9ni$ed as an expen58 an equiv¥knnl valu8. Poll¢l•s r•lallng lo •$$•ts, Ilabllltl•s •ndpmvllons •ndolh•r m¥tteTS. T•nglbl• Ilx•d•ssrfs Tan91b fixed assels ar• measured al 1r orynal cosi valuo. or subsequBnt rtvaKJ•i. or rf d¢)nat•d. M d•s¢ribed ¥bo¥e. Cost valu• ijcludes am costs eyr%Jod ith bnr4irg the asset Into 11$ Innded woFkirvJ c0fvaltn D¢precialion has been ProWd al the fc4kMing I•1 in or(l¥ lo 11• ofl its •s•ets lo inii¢W•lgd va Ovor th•ir Mtim•l¢d Lpjefil lfft8. Plant and machir ¢YW 3 y••rs A regulAr annual rtivi d Ihè likelihorx1 of as1 mp•wnwnt • undertaken. Stock¥ and work In progr8S$ Slo¢k Is valued at Ihe lower of ¢o8t and [1 r•alk%•b val. Fund AccountSng UnstnCted funds art for use at +Jis(yebon of the tru5•S in ILwlherance ol th? 9•neral o*ctNe8 ol th• Charty. There are no end¢xmenl fijnds.
Ocular Melanoma UK Notes to the Accounts for the yeai ended 31 m?h 202S 2 Liabi5ity lo tsxation The Trustees consthr that the tharity $ab"sfS Ihe tests Set (rt in P¥a9raph I Scheduk 6 of the Finance Act 2010 for UK corporation tax purposes. ACCd1Jty. the Chanty ts $entIo1 exempl Irorn wty¢n In iespecl of income Of capiial gains [?Ned within categoS covered by chapter 3 part 11 ol It corporat Tax Act 2010 or Secbon 256 ef the Taxation ol ChaTge#ble Gains Act 1992, to the extenl Ihai such income or gain5 are appl exclusively on the specific Charitable oty¢¢ls of Ihe charity aTrJ for no other purpose. Vue AAded Tax s not reco¥rable by the chanty. and 1$ Iherefere Included in Its re¥1 ¢o$ls in Ihe Stalemenl of Finanty¥l Acts5. 3 Winding up ¢1 dl8$olutSon of th• charity If upon winding up or dissoluiion of It charty the remain any 8$sels. after Il S¥li$fa¢tson ol 811 debts aTrJ liabilitie5, ItK ¥$sets iepffjsnted by Ihe accwnulaled lund sh•ll t• translerred to soD Olhw ¢h•ritable bc#Jy or bad$ hawn9 $imilar objects lo the chanty. 4 Slgn5fKanc• of fln•n¢lo1 Instrum•nts to th• charity• pts¥10n There are no $vJnrficanl ImF4lcatnS of such matters 5 N•t surplus lorn lax in th• fin4nGi•l 2025 2024 Th¢ nel SuUl belor• lax In finanual y•ar stated aftw charg1ry.'- D•we¢i•iion 01 ft¥ed 855•ts P•rAion ¢ts 142 2.429 243 3,888 $ Staff costs and •molum•nts S•l•ry ¢osts 2025 2024 Gr6 Salari jir9 tru8lee5 and kty mio•g•m•nt pmonl Employ•r'$ operalin9 $ts of defined ¢onlrulion pen5Kn $¢h•mes 82.885 97,851 2.429 3,888 Total sala. wagm •nd r•l•t•d ¢o•ts 85.314 101,737 The 8¥erage numter of full lime stalf employed in the year was The e51im8tod full equivalent numier ol $iaff eftwSoyed In Ihe y•ar w•• Th• eSiim•i•d•qulval•nl numb•rof fvll tlm• ¢l¢plo>Ydln dffW•nt•d•11•S In tho ywr ws.". Effja9ed on ¢hOrrtab actMIS Th• Sllm•i•diull Ilfft• •quiv•lthtnumb•r 011 stsff wTrployeds •bo¥• Neither the trustees nor any perw$ cmnecled tth Ihem ba% rece any lra110n fr Ihe ¢hanty or any relaled •niity, either in the curnent or prnr yèar. No employees re1¥¢d emrluments lexduding ¢ost&l in ex5 of£60.Lf#) per •nnurn. 7 Defined contribution penslon sch•m•s Any118bilile8 and asse15 a5$0cialed with the scheme are shrth urth debtus aTrJ credilors. 23
Ocular Melanoma UK Notes to the Accounts for the year ended 31 March 2025 B R•mun•ratton and payments to Trusteès and pèr50ns conn•ct•d with them 2025 2024 R•tyun•r•lionp•1o t¢+ or conn•d•épwsons No Irustres or ¢onne¢ted persons re¢eW remMira*"or 9 Trust•8s' •xp•ns•s No twslee expenses were incwred. oither in Ihe cwrenl or hwr. 10 Tangible fix•d as8•ts Curr•nl Y••r Land and 8ullthng6 Pl•rt & IAachlnery Motor Vehlcles Total Cost At l ri1 2024 Addilior 3.552 3.552 At 31 M•r¢h 2025 3.SS2 3,6S2 D•pr•clallon At 1 April 2024 Chafge for the year 3.314 142 3,314 142 At 31 M•r¢h 2025 3.458 3.458 N•t book v•lu• At 31 M•reh 2025 98 At 31 M•r¢h 2024 231 238 Prlor Ymr L•nd •nd Bulldlngs pbrt& MacNrnry Motor Vehlcle¥ Tol•l Colt 01 2023 Adilions 3.552 3.SS2 31 Il•r¢h 2024 3.552 3.552 Depreclatlon 01 rit 2023 Charge for the year 3.071 243 3.071 243 31 Alar¢h 2024 3.314 3.314 N•t book v•1 31 March 2024 238 230 01 WI 2023 401 481 24
Ocular Melanoma UK Notes lo the Accounts for the year ¢nd¢d 31 March 2025 11 Stocks & Work in Proprus 2025 2024 Stoths befoTe wnte d¢Nr 2.108 2,108 12 Debtors 2025 2024 Trade dobiors 22.884 22,884 13 Cr•dltor8.' amounts lalllng wlthln on• y••r 2026 2024 Trade creditor5 cnja 776 1,738 1.604 14 Incom• and Exp•ndSiur• account •ummary 2025 2024 At 1 Aprll 2024 Surp$ after tax lor y¢or 78.015 7.442 78,703 16881 At 31 M•r¢h 2025 85.457 78.015 15 No r•latgd rtY transaetlom No tNst¢• or otr person r•L•ted lo th¢ Chaity h•J arry pbrnoml int•r•si •ny contracl or tr•rysKtsoTh •nt¢red into by the charity duriThJ the year. 16 P•rtl¢ularn of how yrtlcular funds ar• r•pr•s?nted by 4s•ets •nd li•blllll¢• At 31 March 2025 lknwvdlrfct•d D••19Nt•d Iwd• Rtsiwl¢hd lund• Tot•1 Fun Taryibk• Flxed Assets CurrentA83ets Curtyit LIable8 60.189 11.7361 26.908 87.097 11.7361 S8,$49 26.908 85.457 At 1 Awll 2024 D•#i4n•hd nds R•*lrtcl•d Tot41 Fund$ Tarvjibk Fixed Assets Cuffenl Assets Currenl Liabrfib"e$ 238 42.774 1.6041 238 79,381 11,6041 36,607 41A08 36,607 78,015 25
Ocular Melanoma UK Notss to the Accounts for the year ended 31 March 2025 17 Chang¢ in totsl fvnds owr thè y•ar as shown In Not• 16 . anatysed by Individual funds Funth bri9 MOnI In Tr•nbl•rs lorw•rd Irorn In 2025 b•tsw•n 2024 lunth Irt 1025 Pund• c4rrl•d fonnrd to 202$ UnT•strIct•d•ndd•slwffUn9... Llnre8tnct8d Re¥enu• Funds 41.408 17.141 $8,549 Total Urntrl¢t•d •nd dMl9n•i•d furrfl• 41.401 68,$49 R•sirl¢i•dlunds.'. Annual Conf¢ien¢• P•11 fokler Patwnl Infonnalim to prffKk 8taTrJard R•$our¢4s HCP Trial Databa Helpline Advisor Rele aThJ S Py$¢hologi¢al Support Educational Ev•ni 7.167 3.675 1.883 2.333 2.333 10.544 4.839 3.833 16.6671 soo 3.675 1,710 11731 1,768 125 18.C691 817 2,458 4,47S 5,656 4.333 Tot•1 r••trfj¢t•d fvnds 9,699 26,908 Total charlty ld5 78.015 7.442 85.457 18 An•ly81• of movements In fund• th• y••r • •hown In Not• 17 olr GBlnB & MLw•m•Dt I In¢om• Exp•ndllur• 202• 2025 2026 Unrestrlctvd•ndd•slgn•t•d fvn... Unresiricled Revenue Funds 111.019 193,8781 17,141 Conl•r*nce PtnI fokl•f patnI InfoimatKn 10 itaThJwd Retsourtes HCP Tri81 Database Helpline Advisor Role ar¥J SLWrt F¥seh¢l)gical Support Educational Event 24.349 131.0161 16,667) 16.7fy) 118.8731 11731 1.768 12S 16.0891 817 11.7751 120.1041 19.6631 14.035 10.5(KI 173.461 7.442 26
Ocular Melanoma UK Notes to the Accounts foi the year ended 31 Mah 2025 19 The purpos•s for which the funds as Unresirict8danddeslgrtated funtts... These lunds aTe lor the et[j Ihe otpctives of the chanty. Io provth reser%e$ lor future acb¥itse5, arnl. $'ecI lo tharity i$labon, are e fr£ am restrKbttlS on their use. Unre$trided Re¥enu8 FuTrJs R•strlct•d lunds.". Restricted fvnd5 are funds that donors have 9i%n for a particuLqi purpwe an1 kY¢4e¢l os outtined by donors and may indude other ¢th1Cled cost5. ain and use of eath restricted fund are delaikd In the notes ol tho fiMn¢AI st8t•ments. Restricted R•v•nu• Funds 20 Ultimat• controlllng paty The charty Is under the Contr of 115 Wl ftwnbers. Every member of the chafity obliged lo cOn1nrt& $u¢h wnounl Bs may be required exc••drs E10 10 lh• a&68t8 of the company in Ihe ol its beiThJ wound up he Th she 15 a rnr. or within om y•¥r oftei hg or 8he c••s•$ lo t¢ • m•mLr. 27
Ocular Melanoma UK Détailed analysis of In¢om• and expenditur8 for tho yèar •nded 31 March 2025 as r¢quired by the SORP 201$ This analysls 1$ classsified by ¢onv•ntional nominal descriplions andnol by activlty. 21 Donations. Grants and Legacles Currort y••f Curr•nt y•¥r IknT•SWlct•d R•id¢t•d Fun Furb Current y••r Tothi FuThd¥ Prfor Y¢ar Totsl Fund 202S 2015 2025 2024 Small ¢Jonations individually less than £1(KN) 8rK)nYrThj do)& 30.057 30.057 2,943 21.996 2.329 CLS UK 1.000 In Merr lo.8 10.802 13.786 Totsl donatlons glfts from Indlvldualx 39,111 43.802 43.802 Oonatlonl and 9fft• Irom Indl4bdu•l• IlrKlud• HMRC rnlund• on offt ¥ld•d don•tlon•l. Prfor Y•ar anal• Prtor Y•r PrtQF Y••r lknr•tri¢t•d R•¥tdei•d FundB Fund• Prf•rY••r 70ts1 Fur 2024 2024 2024 Prlor year 39,111 Cury•nt )wr Currnni y•Av Cuvr•rt yMr Toi•l Fun Prlor Y•r Tot41 Fund¥ 2025 2025 242S 2024 L•gocS0• f•ulvabl• IMJH 10,C 10.000 Tot•1 legach• rK•l¥•bl• 10,IIIKI 10,IXIO L•gacl•• r•c•lvabh. Prfor Ygar anal1¥ PrforY••r Pflor Y••r UmM•irl¢t•d R•stri¢t•d Fur Prlor Y•ar T•tal Fun 2024 2OZ4 2024 Prlor y•ar 28
Ocular Melanoma UK Detslled analysi$ of Income and expenditure for the year ended 31 March 2025 as required by the SORP 2015 Revenue grants •nddon•tths from non wblk bodi•s Cyrrerrt ye•r Curr•nt yw currnnt year Prfor Y•ar Lkntrkt•d R•sth¢W Taial Fund¥ Toiol Fund• 2025 2025 2025 2024 Dekalh Sy7lems Ltd 15,000 15,1100 11.(KKI 1nynurOr6 LSmfted 32,C(#) 32,000 32,C Aura BSe1£11t1$ 22.884 22.884 sion FOundatn Alan eoswell Cty AIA 3,022 Souttr Charil801• Tfusl TriS8lus Lrfe Soen¢• Ideaya BK)sceS Total prl¥Jt• wctor r•v•nu• grant• 69,884 72.384 64.022 R•¥enw grant• and don•tlon• from non publlc t1•4 Ilndud• Glft Ald donth• Irom •ub•ldl•rb••l Y•ar anal1• Prlor Prfov Yw UnrMlvlct•d R•iid¢i•d Fw Prf¢v Y• Prlor Yvr TthI Fund• 2024 2024 2024 Prfor Y•ar 3.022 61.LK(I 64,022 29
Ocular Melanoma UK Detailed analysis of in¢om• and expenditure for the yèar ended 31 March 2025 as rèquirod by th• SORP 2015 Total Donations. Grants and Legacies Unro5trict•d Restri¢trd Current Y•Jr Fund Toi¥l Funds Pr4ty Y••r Tolal Funds Current yw 2025 2025 202$ 2024 Total Donations, Gr•nts and Looaci A1 56,302 126.186 103,133 Unrestrktad R•Strid Fun Funth 2024 2024 Priory••r Tothl Fun 2024 Total Donatlons, Grants and Leqacl•8 A1 42.133 61,000 103.133 22 Incom• from charltsbl• a¢tlvltl•s- Tradlng A¢tlvltl•s Curr•nt y•¥r ywr Cmnt y••w R•strlGt•d Fund¥ ¢urr•nt y•ar Tothi Prlor Year To¢•1 Funth 2025 2025 2025 2024 Prlmary purpo•• •nd •nclll•ry trodlng Sale of goods and servicw in accordw with the charills objects 247 247 325 Total Prlm•ry purpov and anelll•ry trJlny 247 247 325 prtoryer prtar Y••r Unrwtrtcwd R•strl¢t•d Fund¢ 2024 Pvlor Yur Tcéal Fun 2024 2024 Prlmary purpoJ• and *neIl1 tradlng Sala of goods a1 seNces in acejjr wilh ttte eharitls objects 325 325 Total Prlmory purpoa• and anclllary trathrvJ 325 325
Ocular Melanoma UK Detailed analysis of income and expenditur• for the yoar ond•d 31 March 2025 as required by the SORP 2015 23 TO Incrrtne from ¢harl¢abl? xtl¥ill•s Cvrrent r Currnnt year curr IinreslVlCted 0#¢1•0 TWI F¥n4ts Fur Funds Prlor Y•ar CutrTrnl y¢or Total Ftsnds 202S 2025 2025 2024 Total from charilae traJiryJ 247 247 325 Total fr¢)m eharftabl• a¢¥51 247 247 325 In¢om• from ¢h¥rl¢obkn ocllvltS0. Prlor Year anal Prlor Yur Pdor Y•r Prlor yvar Fun Total Fund¥ 24 2024 Tol81 income Irom c•e tr8dir 325 325 325 325 31
O¢ular Melanoma UK Dgtailgd analysis of incom• and •xp•nditure for the year ended 31 March 2025 as re9uired by the SORP 2015 24 Income from othèr. non charltsbl¢. trading activities Curmty••t Cwr•rtt Curr•nt year Llnr•stnc (esthcted Tot•1 Fund* Prtor Y••f Totsl Fund5 2025 2025 2024 I1me l¥om fur181$1 events 53.531 53,531 45,317 Total fr<)m othor a¢tl¥lll•• 51531 53.531 45.317 Income from othgr. non charltabl•. tra9 •ctlvitSes. Prfor Yr Fun Furb Y4)tsl Fthi Pylor Y•af 45.317 45,317
Ocular Melanoma UK Detailèd analysi$ of In¢ome and expenditure for th8 ar •nd•d 31 March 2025 as required by the SORP 2015 25 Expendlture on charitable activities - Dlre¢t Syndlng Curyeftt yè•r Current y•ar Currwt r Prtor Y•ai Total Funth Totsl Fund Curr•nt Year Funth Furbds 2025 2025 2025 2024 Gross w4e5 arKI s8laries. charilat40 59.777 23,1Ck8 2.885 97.851 Defined conlritwtKJn costs - charitable activities Travd 8Th1 St*>slstenc•. Chalita+ Activities Markeliro and adv•li5irvJ of ¢harilable sarviess Charitsbb acliwtKes cosls Staff welfare 2,429 3.886 2.828 747 3.918 S.250 2.253 261 52.475 54.728 261 26,706 Total dlr•ct sp•nding 824 71,466 76.915 148,381 129,308 All thè èxpethlrtu in the pr year was unrestrict•d. Yw Prl•r Y••r Pvlor Ymr Tot•1 Fundi Prlor Yr Fun 2024 2024 2024 Gross w4•s aThJ $alrn. atliviliès Defin ¢onlributK)n FertJth costs charitable a¢liwlles Travel and Subsistere- Chadt8bl Activit8 MarkgtiThJ and thertisiTrJ ol chantaNe seNices critable 8Cti¥riti95 costs 66.951 97.851 747 747 118 1.395 25,311 26.708 Total dlre¢t sp•ndlng 82a 73.097 56,211 129.308 33
Ocular M•lanoma UK D¢talled analysis of incom• and expendlture l¢r th¢ •nded 31 March 2025 as required by the SORP 2015 26 Support costs for ¢haritsblè activities Cutt•fit y•ar Curr•nt y••r Current year Pflly Y••r Total Funth Total Fund¥ Curronl Year Funds Funds 2025 2025 2025 2024 Employee cost5 not includedin dir•cl Costs Recruitmenl expenses Adminlstrativ• ov•rh••ds Taepho. lax and intemel Slalionery ènd prinlir#J m8mLrshiP surI1p¢8 Sthrfare Iicences aThJ 4xpgn SuThYry expenMs In$uran¢e 256 1.788 1.949 257 2.959 5,308 32 1.019 1.885 597 2.662 2,682 257 2.959 32 1.019 907 Prol•$slonal loes pald to a¢fvl$ors other than audltoror •x•mlner Aceounlancy fees other than èxaminaiitsn or alit fees 952 Other legal aTrJ wlessh)nal 1.832 1,772 3,484 5.363 Flnanclal cosls 8ank charges Deyeu'8lK)n & ArTr)rtiSa1 in total for I perkmj 97 132 142 142 243 Support co•t• b•lor• r••llo¢atlon 14,411 17.079 16.499 Totsl 8upp¢rt Costs- Curr•nt Y••r 14.411 17.079 16.499 The ba6+s of allocal¥)n tsf tsjsts tstIeS i8 descriw accounTr3 [X)I1•S All Ihe expeile in th8 prior was unrestr1d. 27 Other Exp•ndltur•- Gov•rnance ¢osts Currotyt y••r Currerrt •T Curr•nl y••r Tothi Funds por Y••r Total Funds Curr•nl Y••r Fur 2025 2025 2025 2024 IndgpeTrJenl Examiners le8S 1,224 1.170 Total G0Man¢• 1.224 1.170 All the expenditure In thè wjr y8ar wa¥ trict.
Ocular Melanorna UK Detailed analysis of incom• and expenditure for t y•a¥ •nd•d 31 March 2025 as required by the SORP 2015 28 Total Charitabl8 gxwndfture y••r Curr•nt year Curr•rrt y••r Prlw Y••1 TfA•I Fun Total Funds Currnnt Y•Ar Furbth Funds 2025 2025 202S 2024 Total dir£d spendiry Totsl ¢harilable Iradir¥J costs Tolal suFwrt C051s Total Govemance costs 82a B2b 82d B28 71.466 76.915 148.381 129,308 14,411 1.224 17.079 1.224 16.499 1,170 Total charltabl• ¢xp•ndltur• 07.101 79,583 166.684 147,011 prtoryw Pvlw Y••r Pdor Y• Prior Y•ar Fund• 3024 2024 Total direct spendirq Totsl charitst4e Iradirva costs Tolal suppjrt costs Toial Go¥em8nce costs 82a B2b 82d B2• 73.097 56.211 129.308 16.499 16.499 1.170 Total ch#rltabl• •xp•ndltvr• 56,211 147.011 29 EXp0ndlr4 on ral•Sn9 funds and cosls ol Investment management Cyrr•Trt y••r Curr•nt yew Curt•rt y•w Y••f vnrmtricth T4x•I Funds Tot•1 Fun Current Y•ar 2025 2025 2025 2024 Cost oi fuThJraisirKJ actiwties 6.777 0.777 2.972 Tolal fundra1 C1# All the expenditure in the wor yèw was unreslrKl&J. B1 6,TT7 6.777 2,972 35